Michel Farnier
Université de Bourgogne(FR)Centre Hospitalier Universitaire de Besançon(FR)Maison des Sciences sociales et des Humanités de Dijon(FR)Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires(FR)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Mutations in PCSK9 cause autosomal dominant hypercholesterolemia(2003)2,977 cited
- → Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events(2015)2,268 cited
- → ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia(2015)532 cited
- → Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel(2015)376 cited
- → Action of Atorvastatin in Combined Hyperlipidemia(2000)235 cited
- → 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia(2017)200 cited